Standard Practice for Testing for Whole Complement Activation in Serum by Solid Materials


Importancia y uso:

5.1 Inappropriate activation of complement by blood-contacting medical devices may have serious acute or chronic effects on the host. This practice is useful as a simple, inexpensive screening method for determining functional whole complement activation by solid materials in vitro.

5.2 This practice is composed of two parts. In Part A (Section 11), human serum is exposed to a solid material. Complement may be depleted by the classical or alternative pathways. In principle, nonspecific binding of certain complement components also may occur. The alternative pathway can deplete later-acting components common to both pathways, that is, components other than C1, C4, and C3 (1).4 In Part B (Section 12), complement activity remaining in the serum after exposure to the test material is assayed by classical pathway-mediated lysis of sensitized RBC.

5.3 Assessment of in vitro whole complement activation, as described here, provides one method for predicting potential complement activation by medical materials intended for clinical application in humans when the material contacts the blood. Other test methods for complement activation are available, including assays for specific complement components and their split products (see X1.3 and X1.4).

5.4 This in vitro test method is suitable for adoption in specifications and standards for screening solid materials for use in the construction of medical devices intended to be implanted in the human body or placed in contact with human blood.

Subcomité:

F04.16

Volúmen:

13.01

Número ICS:

11.100.30 (Analysis of blood and urine)

Palabras clave:

biocompatibility; blood compatibility; whole complement testing;

$ 1,229

Agregar al carrito

Norma
F1984

Versión
25

Estatus
Active

Clasificación
Practice

Fecha aprobación
2025-02-15